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3Abstract
Objectives:
To describe antiretroviral therapy (ART) use and clinical status, at start of and during
pregnancy, for HIV-positive women receiving ART at conception, including the
proportion conceiving on drugs (efavirenz and didanosine) not recommended for use in
early pregnancy.
Methods:
Women with a pregnancy resulting in a live birth after 1995 (n=1,537) were identified in
an observational cohort of patients receiving HIV care at 12 clinics in the UK by
matching records with national pregnancy data. Treatment and clinical data were
analysed for 375 women conceiving on ART, including logistic regression to identify
factors associated with changing regimen during pregnancy.
Results:
Of the 375 women on ART, 39 (10%) conceived on dual therapy, 306 (82%) on triple
therapy and 30 (8%) on >3 drugs. In total, 116 (31%) women conceived on a regimen
containing efavirenz or didanosine (69 efavirenz, 54 didanosine, 7 both). Overall, 38%
(143) changed regimen during pregnancy, of whom 44% (n=51) had a detectable viral
load around that time. Detectable viral load was associated with increased risk of
regimen change (adjusted odds ratio 2.97, 95% confidence interval [1.70, 5.19]), while
women on efavirenz at conception were three times more likely to switch than women
on other drugs (3.40, [1.84, 6.25]). Regimen switching was also associated with year at
conception (0.89, [0.83-0.96]).
4Conclusions:
These findings reinforce the need for careful consideration of ART use among women
planning or likely to have a pregnancy in order to reduce viral load before pregnancy
and avoid drugs not recommended for early antenatal use.
Keywords: HIV; pregnancy; antiretroviral agents; antiretroviral therapy; United
Kingdom.
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With the advent of reliable therapy to delay disease progression and prevent mother-to-
child transmission (MTCT), an increasing number of women known to be HIV-positive
are having children; currently >1200 deliveries are reported annually in this group in the
UK [1]. Around 70% of these are among women diagnosed prior to pregnancy, half of
whom are on combination antiretroviral therapy (ART) when they conceive [2].
Unique considerations apply to ART use during pregnancy reflecting the dual goals of
preventing transmission and delaying maternal disease progression, while considering
the needs of the developing fetus. All HIV-positive pregnant women in the UK are
recommended ART to prevent MTCT as well as for their own health if required [3].
Women conceiving on therapy are recommended to stay on the same regimen
throughout pregnancy unless it is failing and those not yet on therapy are
recommended to initiate ART after the first trimester, the period of greatest concern for
teratogenicity [3].
Efavirenz together with a nucleoside backbone is the recommended first-line
combination ART regimen in the UK [4] but current guidelines recommend that women
who are likely to conceive avoid its use due to safety concerns [3]. Limited animal study
data and case reports of neural tube defects in infants exposed to efavirenz in the first
trimester form the basis for these concerns [5,6,7]. Birth defects, including neural tube
defects, were observed in 2.8% live births with first trimester exposure to efavirenz, as
reported to the Antiretroviral Pregnancy Registry [8]. However, observational cohorts
indicate that the prevalence of all congenital abnormalities is not significantly higher
among infants exposed to efavirenz in utero than to those exposed to other
antiretroviral drugs [9,10,11]. There are insufficient data to exclude a small increase in
the risk of specific malformations and it is recommended that women wishing to
6become pregnant in the UK are treated with nevirapine-based regimens (if their CD4
count is <250 cells/mm3) or boosted protease inhibitor-based regimens (PI) [4].
Didanosine, no longer widely used, may be associated with a higher incidence of birth
defects in exposed infants compared with commonly used antiretroviral drugs; birth
defects occurred in 4.7% live-births with first trimester exposure, although no pattern of
defects was seen [8]. While UK treatment guidelines recommend that women who may
conceive avoid using efavirenz or didanosine [3], they also recommend that if women
conceive on these drugs they should continue this regimen, unless it is failing [3]. The
rationale for this recommendation is that if a woman conceives on efavirenz and then
switches treatment, the fetus is unlikely to avoid exposure during the period of initial
neural development because the drug has a long half-life and there is normally some
delay before presenting for antenatal care [3].
Through data linkage of two observational HIV studies in the UK, we identified women
who were receiving ART at conception of their first reported pregnancy. Our objectives
were to describe the virological, immunological and treatment characteristics of these
women, including the proportion using efavirenz or didanosine at conception, and to
investigate the frequency of and risk factors associated with antenatal ART switching.
Methods
Data collection
The UK Collaborative HIV Cohort (UK CHIC) is an observational study collating HIV-
related clinical data from many of the largest HIV clinical centres in the UK (see
Appendix). UK CHIC includes demographic data, dates and results of all CD4
count/viral load assessments, and dates of starting and stopping ART drugs; data on
pregnancy status is not reported. UK CHIC includes approximately one-third of HIV-
7positive individuals receiving care in the UK over this period and is described in detail
elsewhere [12].
Through the National Study of HIV in Pregnancy and Childhood (NSHPC), data on
HIV-positive women diagnosed prior to or during antenatal care are collected from
every maternity unit in the UK/Ireland through confidential quarterly active reporting.
Data collected includes demographic details, timing of maternal diagnosis, expected
date of delivery (EDD), date of delivery, pregnancy outcome, dates and results of CD4
count/viral load taken during pregnancy and ART use at conception and during
pregnancy. Further details are available at www.nshpc.ucl.ac.uk, and elsewhere [2].
Identifying women with a pregnancy in the UK CHIC dataset
Women in the UK CHIC dataset who had a pregnancy were identified by matching
records to the NSHPC dataset. Both UK CHIC and NSHPC datasets are
pseudonymised. Initially, records in the NSHPC dataset were linked to records in UK
CHIC using maternal date of birth (DOB) (Fig. 1a). Other data fields were then used to
confirm matches between records linked using maternal date of birth. Records with an
exact CD4 date match were confirmed as a match if they also had either CD4 count
(±10 cells/mm3) match on that date, had attended the same hospital or had identical
HIV diagnosis dates (b). The same criteria were then used to identify matches between
records which had matching CD4 date ±30 days (c). Records which did not have
matching CD4 dates ±30 days but had matching drug start and/or stop dates were then
confirmed as a match (d). Further matches were manually identified from the remaining
linked records using drug start and stop dates, date of HIV diagnosis, country of birth,
and viral load dates (e). Mortimer Market Centre, which provides HIV services, is
closely located to University College Hospital, which provides maternity care; during
the matching process these were classed as the same site.
8Figure 1. Diagram showing the matching process between records in the NSHPC and
UK CHIC datasets.
Footnote: Brackets indicate the number of records linked.
Study population
A total of 1710 records for women seen for HIV care between 1996 and mid-2009 were
matched to a record in the NSHPC dataset. Matched records were representative of all
records in the NSHPC dataset, with respect to factors including ethnicity, mode of HIV
acquisition and clinical status. Further records (n=144) were linked using maternal
DOB and hospital but could not be confirmed as a match due to missing/discrepant
site, diagnosis date or CD4 data. Pregnancies resulting in termination (n=61),
miscarriage (n=92) or stillbirth (n=17) and ectopic pregnancies (n=2) were excluded as
well as one case where the woman left the UK before delivery. Of the 1,537 women
with a pregnancy resulting in a live birth, 720 (47%) were in HIV-related care before the
start of their first pregnancy reported to the NSHPC (typically their first pregnancy since
HIV diagnosis and/or arrival in the UK); 375 (24%) women were on ART at time of
conception of their first reported pregnancy, representing 52% of those receiving
clinical care. This group of 375 women forms the study population for the current
analyses.
Variables and definitions
Duration of pregnancy varied and actual date of delivery was up to 98 days before
EDD, therefore estimated date of conception was calculated as 266 days before EDD
(normally calculated using ultrasound scan) or before actual date of delivery if EDD
was not reported. Data from UK CHIC were used in the analysis; where demographic
data or date of diagnosis was missing from this dataset, data from the NSHPC dataset
9were used. Viral load was defined as undetectable if it was below the detection
threshold of the viral load assay used at the time, typically <50 copies/ml.
Data analysis
A regimen switch was defined as a discontinuation or introduction of at least one ART
drug during pregnancy. The Kaplan-Meier method was used to estimate median time to
first regimen switch. Fisher’s exact test was used to assess changes in drug use over
time. Univariate and multivariable logistic regression were used to identify factors
associated with any regimen switch; factors considered included type of ART at
conception, viral load at conception and calendar year at conception. Data analysis
was undertaken using SAS 9 (SAS Institute Inc. Cary, NC, USA).
Results
Characterising women on ART at conception
Almost three-quarters of the 375 women on ART at conception were black-African and
the vast majority were infected heterosexually (Table 1). At conception, median time
since HIV diagnosis was nearly 4 years; half were severely immunosuppressed (CD4
<200 cells/mm3) around the time of HIV diagnosis (within 90 days of diagnosis in the
UK and before starting ART) (Table 1). The median time since starting ART was 2.4
years and one-fifth (n=81, 22%) had initiated ART in the 12 months prior to conception.
Ninety-three percent of women had a CD4 count <350 cells/mm3 at time of initiating
ART (Table 1).
By the time of conception, median CD4 count had substantially increased and 74% of
women had achieved undetectable viral load (Table 2). Median viral load among the
27% of women with detectable levels at conception was 900 copies/ml (interquartile
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range (IQR) 134-5914 copies/ml). The majority of women with CD4 <200 cells/mm3 at
conception (n=44) had also been severely immunosuppressed at diagnosis (81%,
21/26, where data was available), which occurred a median of 16 months before
conception in this group.
ART use
The majority of women were receiving a combination of three ART drugs (n=306, 82%)
and NNRTI-based regimens predominated (Table 2). Of the 39 women on fewer than
three drugs, 38% (n=15) conceived after 2005. One-third of women (132/375, 35%)
were using a regimen containing nevirapine; 18% (n=69) were using efavirenz and
14% (n=54) didanosine, including 7 women (2%) using efavirenz and didanosine. Of
those using efavirenz, 43% (n=30) were on their first regimen, 25% (n=7) had efavirenz
in their first regimen but had changed another component of the regimen and 32%
(n=22) had switched to using efavirenz. Of women conceiving on didanosine, 19%
(n=10) were on their first regimen. Overall, at conception women had been on their
current regimen for a median of just under one year. Around half of those conceiving
on efavirenz or didanosine had started the regimen within the previous year (37/69
[54%] and 27/54 [50%] respectively).
The proportion of women using either didanosine or efavirenz at time of conception
was 14% (6/42) in 1996-1999, 37% (50/134) in 2000-2004 and 30% (60/199) in 2005-
2009. The proportion of women using didanosine at conception fell from 30% (7/23) in
2001 to 0 in 2009 (5% (2/40) in 2008) (p=0.07). Use of efavirenz fell from 30% (7/23) in
2001 to 13% (2/15) in 2009 (p=0.7). Four women were on darunavir (two in 2008 and
two in 2009), two of whom were also on etravirine - none of these women switched
treatment during pregnancy. Twenty-one women conceived on atazanavir, of whom 6
(29%) discontinued its use during pregnancy (3 with undetectable viral load and 3 with
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detectable viral load around the time of switch); among these six women, four switched
to zidovudine, one to boosted saquinavir (a protease inhibitor (PI)) and one remained
on a boosted PI. No women conceived on tipranavir.
ART switching during pregnancy
More than one-third (n=143, 38%) of women switched regimen during pregnancy,
including 22 women who interrupted treatment. Regimen switches occurred during the
first, second and third trimesters (62% (n=98), 29% (n=41) and 9% (n=13),
respectively). The median time to switch was 2.1 months (IQR 1.1-4.3 months) from
time of conception. The median CD4 count in the 90 days before regimen change was
290 cells/mm3 (IQR 186-460 cells/mm3). The median viral load around the time of
changing was 50 copies/ml (IQR 50-6047 copies/ml) and 56% (65/116) had an
undetectable viral load at this time.
Fifty-nine percent (41/69) of those who conceived on efavirenz changed regimen
during pregnancy compared to 50% (27/54) of women on didanosine and 24% (32/132)
of those on nevirapine. Most regimen changes among women on efavirenz were
discontinuations of this drug (85%, 35/41), higher than for didanosine (66%, 18/27
discontinued this drug) or nevirapine (53%, 17/32). Among women discontinuing
efavirenz, 17 (49%) stopped during the first six weeks, 9 (26%) between 6 and 12
weeks after conception and 9 (26%) after 12 weeks, the latest at 21 weeks. In contrast,
among women discontinuing didanosine, 4 (22%), 5 (28%) and 9 (50%) stopped in
these three periods respectively. There were also differences with respect to virological
status in early pregnancy, with 25% (8/32) of women switching from efavirenz having
detectable viral load around the time of conception, compared with 56% (10/18) of
those switching from didanosine.
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Among women discontinuing efavirenz, four switched to nevirapine; 13 started a PI
(ritonavir (n=10), saquinavir (n=1) or nelfinavir (n=1)); two started tenofovir and 11
started zidovudine (5 monotherapy). The majority remained on at least one NRTI
(22/35, 63%), two remained on just NRTIs and two started additional NRTIs. Among
those discontinuing didanosine, the most common regimen change was to switch to an
alternative NRTI (zidovudine (n=10), abacavir (n=1), emtricitabine (n=1) or stavudine
(n=1)); one woman started efavirenz and two restarted didanosine in their second
trimester. One woman who conceived on didanosine and efavirenz interrupted ART at
11 weeks, restarting after the pregnancy.
Conception on an efavirenz-containing regimen was the strongest risk factor for
treatment switch identified in multivariable logistic regression. Adjusting for viral load
around time of conception and calendar year at conception, women who conceived on
efavirenz were more likely to change regimen during pregnancy compared with women
on other drugs (adjusted odds ratio 3.40 [95% confidence interval 1.84, 6.25] p<0.001).
Women were less likely to switch treatment in later years even after adjusting for ART
use and viral load at conception (0.89 [0.83, 0.96] p=0.002), (Table 3). Repeating this
logistic regression using drug discontinuation as the outcome produced similar results
(data not shown).
Viral load
Among the 27% (n=84) women with a detectable viral load at start of pregnancy, 51%
(36/70) achieved undetectable levels by their third trimester (52% [23/44] of those who
switched regimen and 50% [13/26] of those who did not). Nearly two-thirds of those
with detectable viral load at the start of pregnancy had been on ART for >1 year (63%,
n=53) with 27% (n=23) on ART for <6 months. With respect to the current ART
regimen, 43% (n=36) of women with detectable viral load around conception had
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started this in the previous 6 months. Thirty-four women had detectable viral load at
both conception and delivery, of whom 13 (38%) did not switch treatment during
pregnancy (3.5% (13/375) of the overall group).
Overall, 82% (252/306) women had viral load below the limit of detection in their third
trimester; among the 54 women with detectable viral load, the median was 289
copies/ml (IQR 113-942 copies/ml).
Transmission
HIV infection status was available for 340 infants. One child (0.3%, 95% CI 0.0-0.9%),
born in 2007, was infected. In this case the mother conceived whilst using lamivudine
and abacavir, additional drugs were included in her regimen during the second
trimester but viral load was not suppressed by delivery.
Discussion
In our study, HIV-positive women conceiving on ART had been diagnosed for a median
of 3.7 years and treated on average for nearly 2.5 years. At conception median CD4
count was 390 cells/mm3 indicating that most women were in good health, despite
many having a CD4 count <200 cells/mm3 at diagnosis. However, 14% started
pregnancy with CD4 <200 cells/mm3, similar to results from other European studies
[13]. The transmission rate was low as would be expected among women conceiving
on combination therapy [14].
Most women (78%) had received ART for over a year at conception. NNRTI-based
regimens predominated, with efavirenz taken in one-third of these. Despite treatment
guidelines recommending that women planning a pregnancy avoid efavirenz or
didanosine, as they may increase risk of congenital abnormalities, almost one-third
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conceived whilst receiving one of these drugs. This is higher than the proportion
reported from an Italian study which reported that 17% of women conceiving on ART
from 2002-2008 were receiving these drugs [15].
Treatment changes during pregnancy may be required due to a failing regimen or
toxicities, or may be prompted by safety concerns. Overall, 38% of pregnant women
here switched regimens, the amount of switching decreasing over time. UK guidelines
recommend that women conceiving on efavirenz should continue this regimen, unless
it is failing. Half the women conceiving on efavirenz here changed regimens, three-
quarters in the first trimester, suggesting that these treatment changes were prompted
by safety concerns. This is supported by our finding that the probability of switching
was 3.26 times greater in women on efavirenz compared with women on other drugs at
conception. In Italy, women conceiving on efavirenz were also more likely to change
treatment during pregnancy than women conceiving on other ART drugs [16].
However, this reflects use of US guidelines which differ from UK guidelines in stating
that women conceiving on efavirenz should change to a suitable alternative if they
present during the first trimester [5].
In our study more than half the women switching from efavirenz did so after the first six
weeks of pregnancy, therefore not avoiding fetal exposure to the drug during the weeks
when neural fusion occurs [11]. Of note, around 80% of women conceiving on
efavirenz-based regimens had undetectable viral loads. Treatment interruptions and
unnecessary switching of regimens that are effectively suppressing viral load should be
avoided, particularly for women already on second-line therapy [4].
Around half the women conceiving on efavirenz had started this within the year prior to
pregnancy, indicating that either they were not planning a pregnancy, did not discuss a
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planned pregnancy with their clinician or were planning a pregnancy but decided to use
efavirenz despite possible risks. Efavirenz is an effective treatment, with health benefits
over non-efavirenz regimens [17] particularly in settings with high levels of HIV/TB co-
infection as it can be used in combination with rifampicin-based TB therapy. In Ivory
Coast, where efavirenz use is common among women, a study comparing pregnancy
outcomes between women conceiving on efavirenz (n=213) and nevirapine (n=131)
observed no visible congenital malformations in either group [11]. Further risk-benefit
analysis is needed regarding the use of efavirenz among women of child bearing age.
Pregnancies which did not result in a live birth were excluded from the analysis,
however it would be of interest, in future analyses, to look at pregnancy outcome in
relation to ART use at conception and treatment switches during pregnancy.
Guidelines recommend that women planning a pregnancy are offered counselling prior
to conception [3] and that HIV physicians should discuss pregnancy plans with women
when making treatment decisions [4]. Our results reinforce this need, both to identify
where increased adherence support or regimen change is required or to discuss
switching to an alternative regimen among women on efavirenz who do not wish to
conceive on this drug. Any changes to treatment should be made swiftly to avoid
switching during or close to the start of pregnancy. Given the probable high number of
unplanned pregnancies in this population [16,18,19], it is important that clinicians
prescribing ART consider that women of childbearing age may become pregnant and
that all HIV-positive women should have access to appropriate contraception and
advice.
Etravirine, a second generation NNRTI, and darunavir, a second generation PI, are
among a handful of drugs approved for use in the past five years. In our study a small
number of women conceived on these drugs in recent years and a larger number
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conceived on atazanavir, a PI approved for use in 2003. It is likely that the number of
women who conceive on these drugs will increase, although little is known about their
safety profiles, and close monitoring of their pregnancy outcomes is thus crucial [8].
Viral load, the most important factor associated with vertical transmission, [14,20,21]
was generally low around the time of conception. However, more than a quarter of
women had non-suppressed viral load at this time (although with low median viral
load), similar to other reports [22]; this group included those who recently initiated ART
(28% within the last six months) but 64% had been on ART for at least one year. This
may be due to delays in treatment switching, previously reported as a concern in the
UK [23]. More than half of those who did not switch regimen, despite having an
unsuppressed viral load at the start of pregnancy, attained viral suppression. Similarly,
in a European study of women conceiving with unsuppressed viral load, 40% of the
women not changing treatment attained viral suppression by delivery [22]. This may be
due to improved adherence during pregnancy, as has been reported elsewhere [24,25],
probably because women receive increased adherence support and/or because they
have increased motivation to adhere. Women on a failing regimen should have
resistance testing [4] and although changing regimen is not always necessary, half the
women who had detectable viral load at the start of pregnancy and did not switch
treatment did not achieve undetectable viral load by the end of pregnancy. This group
might have benefitted from switching treatment.
Median viral load among women with detectable levels in their third trimester was 289
copies/ml compared with 900 copies/ml among those with a detectable viral load at
conception. Given more time some of these women may have achieved undetectable
levels. Although this group represent a small proportion of the overall group, they are at
increased risk of MTCT, particularly as transmission is more likely to occur in the later
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stages of pregnancy [14,20,21]. During pregnancy swift action is required to improve
adherence or change a failing regimen among treated women with a detectable viral
load, to attain viral suppression as quickly as possible.
Linkage between the NSHPC and UK CHIC datasets has allowed us to examine
clinical data prior to as well as during pregnancy. However, several limitations of these
datasets must be acknowledged. Firstly, as with most large observational databases,
both databases may contain missing or incorrect data, resulting in under-linkage of
pregnant women. Secondly, whilst participants in UK CHIC are broadly representative
of the UK HIV population, clinical practice in participating centres may differ from those
at non-participating clinics. Thirdly, UK CHIC does not collect information on the
reasons why women did (or did not) switch treatments, on adherence or ART use prior
to treatment at a centre participating in the study. Finally, the NSHPC does not collect
information on the date when each woman found out that she was pregnant; a date
which is arguably of most relevance for any subsequent changes to her care.
In summary, women planning a pregnancy should be encouraged to discuss their plans
with their physician to facilitate optimal management, including avoidance of
antiretroviral drugs for which there may be specific safety concerns. For women on
treatment, the opportunity to achieve an undetectable viral load before pregnancy and
to maintain this throughout pregnancy should not be missed, given that MTCT can
occur before, as well as during, the last trimester. Clinicians prescribing ART to all
women of childbearing age must consider that these patients might conceive. All
treated HIV-positive women who become pregnant require a high level of clinical
support, in particular those with unsuppressed viral load, who either require a change
in regimen or support with their existing regimen. As the number of pregnancies among
HIV-positive women on ART is increasing [1,22,26] and more women conceive on new
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ART drugs, continued surveillance and monitoring of pregnancy outcomes is vital.
19
Acknowledgments
UK CHIC:
Steering Committee: Jonathan Ainsworth, Jane Anderson, Abdel Babiker, Loveleen
Bansi, David Chadwick, Valerie Delpech, David Dunn, Martin Fisher, Brian Gazzard,
Richard Gilson, Mark Gompels, Teresa Hill, Margaret Johnson, Clifford Leen, Mark
Nelson, Chloe Orkin, Adrian Palfreeman, Andrew Phillips, Deenan Pillay, Frank Post,
Caroline Sabin (PI), Memory Sachikonye, Achim Schwenk, John Walsh.
Central Co-ordination: UCL Medical School, Royal Free Campus, London (Loveleen
Bansi, Teresa Hill, Susie Huntington, Andrew Phillips, Caroline Sabin); Medical
Research Council Clinical Trials Unit (MRC CTU), London (David Dunn, Adam
Glabay).
Participating Centres: Barts and The London NHS Trust, London (C Orkin, N Garrett,
J Lynch, J Hand, C de Souza); Brighton and Sussex University Hospitals NHS Trust (M
Fisher, N Perry, S Tilbury, D Churchill); Chelsea and Westminster Hospital NHS Trust,
London (B Gazzard, M Nelson, M Waxman, D Asboe, S Mandalia); Health Protection
Agency – Centre for Infections London (HPA) (V Delpech); Homerton University
Hospital NHS Trust, London (J Anderson, S Munshi); King’s College Hospital NHS
Foundation Trust, London (H Korat, J Welch, M Poulton, C MacDonald, Z Gleisner, L
Campbell); Mortimer Market Centre, London (R Gilson, N Brima, I Williams); North
Middlesex University Hospital NHS Trust, London (A Schwenk, J Ainsworth, C Wood, S
Miller); Royal Free NHS Trust and UCL Medical School, London (M Johnson, M Youle,
F Lampe, C Smith, H Grabowska, C Chaloner, D Puradiredja); St. Mary’s Hospital,
London (J Walsh, J Weber, F Ramzan, N Mackie, A Winston); The Lothian University
Hospitals NHS Trust, Edinburgh (C Leen, A Wilson); North Bristol NHS Trust (M
Gompels, S Allan); University of Leicester NHS Trust (A Palfreeman, A Moore); South
Tees Hospitals NHS Foundation Trust (D Chadwick, K Wakeman).
20
NSHPC:
We gratefully acknowledge the contribution of the midwives, obstetricians,
genitourinary physicians, paediatricians, clinical nurse specialists and all other
colleagues who report to the NSHPC through the British Paediatric Surveillance Unit of
the Royal College of Paediatrics and Child Health, and the obstetric reporting scheme
run under the auspices of the Royal College of Obstetricians and Gynaecologists. We
thank Janet Masters who co-ordinates the study and manages the data and Icina
Shakes for administrative support.
Ethics approval for NSHPC was renewed following review by the London Multi-Centre
Research Ethics Committee in 2004 (MREC/04/2/009).
Sources of Funding:
UK CHIC is funded by the Medical Research Council (MRC), UK (grants G00001999
and G0600337). NSHPC receives core funding from the Health Protection Agency
(grant number GHP/003/013/003). Data is collated at the UCL Institute of Child Health
which receives a proportion of funding from the Department of Health’s National
Institute for Health Research Biomedical Research Centres funding scheme. Susie
Huntington has a UCL Studentship, funded by the MRC, for postgraduate work. Claire
Thorne holds a Wellcome Trust Research Career Development Fellowship.
21
References
1. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Trends in management
and outcome of pregnancies in HIV-infected women in the UK and Ireland, 1990–2006.
BJOG 2008; 115:1078–1086.
2. National Study of HIV in Pregnancy and Childhood. Obstetric and paediatric HIV
surveillance data from the UK and Ireland. NSHPC update, September 2010. Available
at: www.nshpc.ucl.ac.uk/slides/NSHPC_slides_Q84_protected.ppt#256,1,Slide 1 Last
accessed December 2010.
3. de Ruiter A, Mercey D, Anderson J, Chakraborty R, Clayden P, Foster G et al.
British HIV Association and Children's HIV Association guidelines for the management
of HIV infection in pregnant women 2008. HIV Med 2008; 9: 452-502.
4. Gazzard B, Anderson J, Babiker A, Boffito M, Brook G, Brough G,et al. British HIV
Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral
therapy 2008. HIV Med 2008; 9:563-608.
5. US Public Health Service Task Force. Recommendations for Use of Antiretroviral
Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to
Reduce Perinatal HIV Transmission in the United States (Updated 8 July 2008)
Available from http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf. Last January 2011.
6. Fundaro C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E. Myelomeningocele
in a child with intrauterine exposure to efavirenz. AIDS 2002; 16:299-300.
7. de Santis M, Carducci B, De Santis L, Cavaliere A, Straface G. Periconceptional
exposure to efavirenz and neural tube defects. Arch Intern Med 2002; 162:355.
8. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy
Registry International Interim Report, December 2010. Wilmington, NC: Registry
22
Coordinating Centre. 2010. Available at: www.apregistry.com/forms/interim_report.pdf
Last accessed May 2011.
9. Ford N, Mofenson L, Kranzer K, Medue L, Frigatif L, Mills EJ, et al. Safety of
efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of
outcomes from observational cohorts. AIDS 2010; 24:1461-70.
10. Townsend C, Willey B, Cortina-Borja M, Peckham C, Tookey P. Antiretroviral
therapy and congenital abnormalities in infants born to HIV-infected women in the UK
and Ireland, 1990–2007. AIDS 2009; 23:519–524.
11. Ekouevi DK, Coffie PA, Ouattara E, Moh R, Amani-Bosse C, Messou E, et al.
Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of
the IeDEA West Africa and ANRS Databases, Adidjan, Cote d’Ivoire. J Acquir Immune
Defic Syndr 2011; 56:183-187.
12. The UK Collaborative HIV Cohort Steering Committee. The creation of a large UK-
based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort
(UK CHIC) Study. HIV Med 2004; 5:115–124.
13. Townsend C, Schulte J, Thorne C, Dominguez KL, Tookey PA, Cortina-Borja M, et
al. Antiretroviral therapy and preterm delivery – a pooled analysis of data from the
United States. BJOG 2010; 117:1399-410.
14. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA.
Low rates of mother-to-child transmission of HIV following effective pregnancy
interventions in the United Kingdom and Ireland, 2000–2006. AIDS 2008; 22:973–981.
15. Baroncelli S, Tamburrini E, Ravizza M, Dalzero S, Tibaldi C, Ferrazzi E, et al.
Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in
prescription patterns, viral load suppression, and pregnancy outcomes. AIDS Patient
Care STDS 2009; 23:513-520.
23
16. Floridia M, Tamburrini E, Ravizza M, Anzidei G, Tibaldi C, Bucceri A, et al.
Antiretroviral therapy at conception in pregnant women with HIV in Italy: wide range of
variability and frequent exposure to contraindicated drugs. Antiviral Therapy 2006;
11:941-946.
17. Hsu H, Rydzak C, Cotich K, Wang B, Sax P, Losina E, et al. Quantifying the risks
and benefits of efavirenz use in HIV-infected women of childbearing age in the USA.
HIV Med 2010 [Epub ahead of print].
18. Fiore S, Heard I, Thorne C, Savasi V, Coll O, Malyuta R, et al. Reproductive
experience of HIV-infected women living in Europe. Hum Reprod 2008; 23:2140-2144.
19. Floridia M, Tamburrini E, Bucceri A Tibaldi C, Anzidei G, Guaraldi G, et al.
Pregnancy outcomes and antiretroviral treatment in a national cohort of pregnant
women with HIV: overall rates and differences according to nationality. BJOG 2007;
114:896-900.
20. European Collaborative Study. Mother-to-child transmission of HIV infection in the
era of highly active antiretroviral therapy European collaborative study. Clin Infect Dis
2005; 40:458-465.
21. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination
Antiretroviral Strategies for the Treatment of Pregnant HIV-1–infected Women and
Prevention of Perinatal HIV-1 Transmission. J Acquir Immune Defic Syndr 2002;
29:484-494.
22. Patel D, Cortina-Borja M, De Maria A, Newell ML, Thorne C. Factors associated
with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral
therapy at conception. Antivir Ther 2010; 15:41-49.
24
23. United Kingdom Collaborative HIV Cohort Study, Lee KJ, Dunn D, Gilson R, Porter
K, Bansi L, et al. Treatment switches after viral rebound in HIV-infected adults starting
antiretroviral therapy: multicentre cohort study. AIDS 2008; 22:1943-50.
24. Bardequez AD, Lindsey JC, Shannon M, Tuomala RE, Cohn SE, Smith E, et al.
Adherence to antiretrovirals among US women during and after pregnancy. J Acquir
Immune Defic Syndr 2008; 48:408-417.
25. Mellins CA, Chu C, Malee K, Allison S, Smith R, Harris L, et al. Adherence to
antiretroviral treatment among pregnant and postpartum HIV-infected women. AIDS
Care 2008; 20:958-968.
26. Myer L, Carter RJ, Katyal M, Toro P, El-Sadr WM, Abrams EJ. Impact of
Antiretroviral Therapy on Incidence of Pregnancy among HIV-Infected Women in Sub-
Saharan Africa: A Cohort Study. PloS Med 2010; 7: e1000229.
25
Table 1. Characteristics and ART history of women receiving ART at conception
(n=375).
n %
Ethnicity White 55 (15)
Black-African 277 (74)
Other 43 (11)
Probable route of infection Heterosexual sex 328 (87)
Injecting drug use 9 (2)
Other route 35 (9)
Not reported 3 (1)
Age Median (IQR) (years) 33 (29 - 35)
Range 16 - 45
Time since HIV diagnosis in the
UK
Median (IQR) (years) 3.7 (1.9 - 6.2)
1 year or less 39 (10)
>1 - 3 years 112 (30)
>3 - 5 years 85 (23)
>5 years 135 (36)
Not reported 4 (1)
CD4 count (cells/mm3) at time of
diagnosis in the UK (n=244) 1
Median (IQR) 238 (130-357)
<200 104 (43)
200-350 182 (32)
>350 244 (25)
Time since initiating (any) ART Median (IQR) (years) 2.4 (1.2 - 4.6)
<6 months 42 (11)
6-12 months 39 (10)
>12m – 2 yrs 76 (20)
>2 yrs – 3 yrs 69 (18)
>3 yrs 149 (40)
CD4 count (cells/mm3) at time of
initiating ART (n=292) 1
Median (IQR) 170 (97- 250)
<200 179 (61)
200-350 90 (31)
>350 23 (8)
Viral load (copies/ml) at time of
initiating ART (n=263) 1
Median (IQR) 52,228 (10,093-157,402)
1 Within 90 days.
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Table 2. ART use, immune and virological status at time of conception (n=375).
N (%)
Number of ART drugs
received 1
<3 39 (10)
3 306 (82)
>3 30 (8)
ART regimen Non-nucleoside reverse
transcriptase inhibitor
203 (54)
Unboosted protease inhibitor (PI) 30 (8)
Ritonavir-boosted PI 95 (25)
Nucleoside reverse transcriptase
inhibitors only
37 (10)
Other 10 (3)
Regimen includes efavirenz 69 (18)
Regimen includes didanosine 54 (14)
Time since starting
current ART regimen
Median (IQR) (months) 11.2 (4.6 - 23.5)
<6 months 113 (30)
6-12 months 84 (22)
>12 months – 2 years 88 (23)
>2 years – 3 years 45 (12)
>3 years 45 (12)
CD4 count
(cells/mm3)2 (n=320)
Median (IQR) 390 (259 - 544)
<200 44 (14)
200-350 88 (28)
>350 188 (59)
Viral load (copies/ml)2
(n=317)
Median (IQR) 50 (50 - 74)
Undetectable 233 (74)
Detectable 84 (27)
1 A PI boosted with ritonavir was counted as one drug.
2 Within 90 days of conception.
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Table 3. Results from unadjusted and adjusted logistic regression analysis of factors
associated with switching ART regimens during pregnancy
Unadjusted Adjusted
OR CI p AOR CI p
ART at
conception
Not nevirapine 1 1
Nevirapine 0.47 0.30-0.74 0.07 0.69 0.41-1.16 0.16
Not efavirenz 1 1
Efavirenz 2.93 1.71-5.01 <0.001 3.40 1.84-6.25 <0.001
Not didanosine 1 1
Didanosine 2.11 1.18-3.77 0.01 1.77 0.94-3.33 0.08
Viral load at
conception
Undetectable 1 1
Detectable 3.32 1.98-5.57 <0.001 2.97 1.70-5.19 <0.001
No VL reported 0.97 0.52-1.80 0.92 1.04 0.53-2.02 0.92
Year of conception
(per later year) 0.88 0.82-0.94 <0.001 0.89 0.83-0.96 0.002
